Skip to main content
. 2024 Aug 26;15:214. doi: 10.1186/s13244-024-01784-8

Table 1.

Patient characteristics

Variables Train, (n = 129) Validation, (n = 32) Test, (n = 46)
Sex
 Male 111 (86) 29 (91) 40 (87)
 Female 18 (14) 3 (9) 6 (13)
 Age, year 61 ± 12 61 ± 14 62 ± 10
 Median interval between two scans, day 53 52 56.5
Status
 Deceased 83 (64) 23 (72) 32 (70)
 Censored 46 (36) 9 (28) 14 (30)
 Median survival time, day 467 475 488
Differentiation type
 Highly differentiated 18 (14) 4 (13) 7 (15)
 Moderately differentiated 100 (78) 20 (63) 34 (74)
 Low differentiated 10 (8) 8 (25) 5 (11)
 Undifferentiated 1 (1) 0 (0) 0 (0)
NASH/NAFLD
 Yes 26 (20) 3 (9) 6 (13)
 No 103 (80) 29 (91) 40 (87)
Surgery
 Yes 67 (52) 17 (53) 25 (54)
 No 62 (48) 15 (47) 21 (46)
PVTT
 Yes 24 (19) 5 (16) 7 (15)
 No 105 (81) 27 (84) 39 (85)
EBRT
 Yes 6 (5) 2 (6) 2 (4)
 No 123 (95) 30 (94) 44 (96)
TAE/TACE
 Yes 74 (57) 20 (63) 27 (59)
 No 55 (43) 12 (38) 19 (41)
RFA/WMA
 Yes 38 (29) 8 (25) 12 (26)
 No 91 (71) 24 (75) 34 (74)

NASH non-alcoholic steatohepatitis, NAFLD non-alcoholic fatty liver disease, PVTT partial or complete portal vein tumor thrombosis, EBRT external beam radiation therapy, TAE transarterial embolization, TACE transarterial chemoembolization, RFA radiofrequency ablation, MWA microwave ablation

HHS Vulnerability Disclosure